Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population
You may also be interested in...
American Heart Association Research, In Brief
Outcomes Study Resuscitates Natrecor
American Heart Association Research, In Brief
Outcomes Study Resuscitates Natrecor
Pfizer Backs Out Of Cardiovascular R&D
Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.